ArticleJACC. Case reports2026
Baroreflex Activation Therapy in a Patient With Transthyretin Amyloid Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reply: Causal Inference Challenges in Evaluating Baroreflex Activation Therapy for Transthyretin Amyloid Cardiomyopathy: A Critical Appraisal.JACC. Case reports · 2026Article
- Causal Inference Challenges in Evaluating Baroreflex Activation Therapy for Transthyretin Amyloid Cardiomyopathy: A Critical Appraisal.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransthyretin amyloid cardiomyopathy (TTR-CM) is a form of nonischemic cardiomyopathy associated with progressive heart failure, persistent symptoms, and reduced quality of life despite advances in medical therapy. CASE SUMMARY: We present a man with TTR-CM and heart failure with reduced ejection fraction who remained severely symptomatic despite guideline-directed medical therapy, cardiac resynchronization therapy, and atrial fibrillation ablation. Baroreflex activation therapy (BAT) using the Barostim device was implanted as adjunctive therapy, resulting in marked symptomatic improvement and significant gains in quality-of-life metrics. DISCUSSION: BAT is an established therapy for selected patients with refractory heart failure. Its role in TTR-CM-related cardiomyopathy has not been well described and may offer symptomatic benefit when conventional therapies are insufficient. TAKE-HOME MESSAGE: BAT may be a useful adjunctive therapy to improve symptoms and quality of life in selected patients with TTR-CM and refractory heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.